US6258601B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antisense modulation of ubiquitin protein ligase expression
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 2000-09-07
•
Granted: 2001-07-10
•
Expires: 2020-09-07
Abstract
Abstract Antisense compounds, compositions and methods are provided for modulating the expression of ubiquitin protein ligases WWP1 and WWP2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ubiquitin protein ligases WWP1 and WWP2. Methods of using these compounds for modulation of ubiquitin protein ligases WWP1 and WWP2 expression and for treatment of diseases associated with expression of ubiquitin protein ligases WWP1 and WWP2 are provided.
Inventors
- 👤 Brett P. Monia
- 👤 Lex M. Cowsert
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 16:28
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1137; C12Y; C12Y603/00; C12Y603/02; C12Y603/02019; A; A61; A61K; A61K38/00; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/315; C12N2310/32; C12N2310/321; C12N2310/33; C12N2310/334; C12N2310/3341; C12N2310/34; C12N2310/341; C12N2310/346; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/582
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
61 words
A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding a ubiquitin protein ligase comprising ubiquitin protein ligase WWP1 (SEQ ID NO: 3) or ubiquitin protein ligase WWP2 (SEQ ID NO: 10), wherein said compound specifically hybridizes with and inhibits the expression of the ubiquitin protein ligase (SEQ ID NO: 3 or SEQ ID NO: 10).
Claim 2
Dependent Claim
61 words
A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding a ubiquitin protein ligase comprising ubiquitin protein ligase WWP1 (SEQ ID NO: 3) or ubiquitin protein ligase WWP2 (SEQ ID NO: 10), wherein said compound specifically hybridizes with and inhibits the expression of the ubiquitin protein ligase (SEQ ID NO: 3 or SEQ ID NO: 10).
Claim 3
Dependent Claim
10 words
The compound of claim 1 which is an antisense oligonucleotide.
Claim 4
Dependent Claim
41 words
The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 14, 15, 17, 18, 19, 21, 22, 23, 24, 25, 26, 28, 29, 31, 33, 34, 35, 37, 38, 42, 43, 47, 48 or 50.
Claim 5
Dependent Claim
54 words
The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 67, 68, 69, 70, 71, 72, 74, 75, 76, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93.
Claim 6
Dependent Claim
16 words
The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
Claim 7
Dependent Claim
14 words
The compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.
Claim 8
Dependent Claim
16 words
The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
Claim 9
Dependent Claim
15 words
The compound of claim 7 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
Claim 10
Dependent Claim
15 words
The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
Claim 11
Dependent Claim
12 words
The compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.
Claim 12
Dependent Claim
13 words
The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
Claim 13
Dependent Claim
49 words
A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding a ubiquitin protein ligase comprising ubiquitin protein ligase WWP1 (SEQ ID NO: 3) or ubiquitin protein ligase WWP2 (SEQ ID NO: 10).
Claim 14
Dependent Claim
49 words
A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding a ubiquitin protein ligase comprising ubiquitin protein ligase WWP1 (SEQ ID NO: 3) or ubiquitin protein ligase WWP2 (SEQ ID NO: 10).
Claim 15
Dependent Claim
15 words
A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
Claim 16
Dependent Claim
11 words
The composition of claim 13 further comprising a colloidal dispersion system.
Claim 17
Dependent Claim
12 words
The composition of claim 13 wherein the compound is an antisense oligonucleotide.
Claim 18
Dependent Claim
38 words
A method of inhibiting the expression of a ubiquitin protein ligase in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of ubiquitin protein ligase is inhibited.
References Cited (Backward Citations)
WO1997037223A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-07-09 | 2005-01-08 | 2005-07-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-07-09 | 2009-01-08 | 2009-07-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-07-09 | 2013-01-08 | 2013-07-10 | $7700.00 | Window Closed / Lapsed |